Prediction of human oral pharmacokinetics using nonclinical data: Examples involving four proprietary compounds

Biopharmaceutics and Drug Disposition

Volumn 29, Issue 8, 2008, Pages 455-468

  Fura, Aberra ^a   Vyas, Viral ^a   Humphreys, William ^a   Chimalokonda, Anjaneya ^a   Rodrigues, David ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Allometry; Cvss MRT method; In vitro scaling; Prediction of human oral pharmacokinetics; Transformed intravenous profile

Indexed keywords

BMS A 56; DRUG; NEW DRUG; UNCLASSIFIED DRUG; PLASMA PROTEIN;

ALLOMETRY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; LIVER MICROSOME; MALE; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; NORMAL HUMAN; PREDICTION; RAT; SIMULATION; SINGLE DRUG DOSE; SPECIES DIFFERENCE; STEADY STATE; ANIMAL; BIOAVAILABILITY; DOG; MACACA; METABOLIC CLEARANCE RATE; METABOLISM; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PROTEIN BINDING;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BLOOD PROTEINS; DOGS; HUMANS; MACACA FASCICULARIS; MALE; METABOLIC CLEARANCE RATE; PHARMACOKINETICS; PROTEIN BINDING; RATS;

EID: 58749116164     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.632     Document Type: Article

References (36)

1. Feng MR, Lou X, Brown RR, Hutchaleelaha A. Allometric pharmacokinetic scaling: towards the prediction of human oral pharmacokinetics. Pharm Res 2000; 17: 410-418.
2. Jones HM, Parrott N, Jorga K, Lave T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 2006; 45: 511-542.
3. McGinnity DF, Collington J, Austin RP, Riley RJ. Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. Curr Drug Metab 2007; 8: 463-479.
4. Fura A, Vyas V, Koplowitz B. Prediction of human pharmacokinetics from hepatic microsomal intrinsic clearance and allometrically scaled preclinical data. Drug Metab Rev 2005; 37(Suppl. 2): 87-88.
5. Lowe PJ, Hijazi Y, Luttringer O, Yin H, Sarangapani R, Howard D. On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development. Xenobiotica 2007; 37: 1331-1354.
6. Dedrick R, Bischoff KB, Zaharko DS. Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 1970; 54: 95-101.
7. Hutchaleelaha A, Chow HH, Mayersohn M. Comparative pharmacokinetics and interspecies scaling of amphotericin B in several mammalian species. J Pharm Pharmacol 1997; 49: 178-183.
8. Mahmood I, Balian JD. Interspecies scaling: Predicting clearance of drugs in humans. Three different approaches. Xenobiotica 1996; 26: 887-895.
9. Bernareggi A, Rowland M. Physiologic modeling of cyclosporin kinetics in rat and man. J Pharmacokinet Biopharm 1991; 19: 21-50.
10. Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 2002; 91: 1358-1370.
11. De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RA. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 2007; 35: 1766-1780.
12. Wajima T, Yano Y, Fukumura K, Oguma T. Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. J Pharm Sci 2004; 93: 1890-1900.
13. Shiran MR, Proctor NJ, Howgate EM, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling. Xenobiotica 2006; 36: 567-580.
14. Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47: 1469-1479.
15. Iwatsubo T, Hirota N, Ooie T, et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 1997; 73: 147-171.
16. Obach RS, Baxter JG, Liston TE, et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997; 283: 46-58.
17. Boxenbaum H. Interspecies pharmacokinetic scaling and the evolutionary comparative paradigm. Drug Metab Rev 1984; 15: 1071-1121.
18. Boxenbaum H, Dilea C. First-time-in human dose selection: allometric thoughts and perspectives. J Clin Pharmacol 1995; 35: 957-966.
19. Mordenti J. Pharmacokinetic scale-up: accurate prediction of human pharmacokinetic profiles from animal data. J Pharm Sci 1985; 74: 1097-1099.
20. Paxton JW, Kim SN, Whitfield LR. Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans. Cancer Res 1990; 50: 2692-2697.
21. Ings RMJ. Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica 1990; 20: 1201-1231.
22. Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 1982; 10: 201-227.
23. Mahmood I, Balian JD. Interspecies scaling: a comparative study for the prediction of clearance and volume using two or more than two species. Life Sci 1996; 59: 579-585.
24. Mahmood I, Balian JD. Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. J Pharm Sci 1996; 85: 411-414.
25. Mahmood I. Interspecies scaling: role of protein binding in the prediction of clearance from animals to humans. J Clin Pharmacol 2000; 40: 1439-1446.
26. Tang H, Mayersohn M. A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry. J Pharm Sci 2006; 95: 1783-1799.
27. Tang H, Mayersohn M. A novel model for prediction of human drug clearance by allometric scaling. Drug Metab Dispos 2005; 3: 1297-1303.
28. Mahmood I. Prediction of human drug clearance from animal data: application of the rule of exponents and 'fu Corrected Intercept Method' (FCIM). J Pharm Sci 2006; 95: 1810-1821.
29. Lombardo F, Obach RS, Shalaeva MY, Gao F. Prediction of volume of distribution values in humans for neutral and basic drugs using physiochemical measurements and plasma protein binding data. J Med Chem 2002; 45: 2867-2876.
30. Ward KW, Smith BR. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time. Drug Metab Dispos 2004; 32: 612-619.
31. Barter ZE, Bayliss MK, Beaune PH, et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 2007; 8: 33-45.
32. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095.
33. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Indust Health 1997; 13: 407-484.
34. Ito K, Houston JB. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm Res 2004; 21: 785-792.
35. Ward KW, Smith BR. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab Dispos 2004; 32: 603-611.
36. Lave T, Dupin S, Schmitt C, Chou RC, Jaeck D, Coassolo P. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J Pharm Sci 1997; 86: 584-590.